Characterization of Patients With Refractory or Unexplained Chronic Cough Participating in a Phase 2 Clinical Trial of the P2X3-Receptor Antagonist Gefapixant

Autor: Mandel R. Sher, David Muccino, Zhi Jin Xu, Lorcan McGarvey, Allison Martin Nguyen, Jaclyn A. Smith, Wen-Chi Wu, Alyn H. Morice, Jonathan Schelfhout, Surinder S. Birring

Publikováno v: Morice, A H, Birring, S S, Smith, J A, McGarvey, L P, Schelfhout, J, Martin Nguyen, A, Xu, Z J, Wu, W C, Muccino, D R & Sher, M R 2021, ' Characterization of Patients With Refractory or Unexplained Chronic Cough Participating in a Phase 2 Clinical Trial of the P2X3-Receptor Antagonist Gefapixant ', Lung, vol. 199, no. 2, pp. 121-129 . https://doi.org/10.1007/s00408-021-00437-7
Morice, A H, Birring, S S, Smith, J A, McGarvey, L P, Schelfhout, J, Martin Nguyen, A, Xu, Z J, Wu, W-C, Muccino, D R & Sher, M R 2021, ' Characterization of Patients With Refractory or Unexplained Chronic Cough Participating in a Phase 2 Clinical Trial of the P2X3-Receptor Antagonist Gefapixant ', Lung, vol. 199, no. 2, pp. 121-129 . https://doi.org/10.1007/s00408-021-00437-7
Lung

Purpose This analysis assesses clinical characteristics of patients with refractory chronic cough (RCC) or unexplained chronic cough (UCC) enrolled in a phase 2 study to better understand this patient population. Methods Patients with RCC/UCC lasting

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::adc3d886357439392e213c2543bf24b6
https://doi.org/10.1007/s00408-021-00437-7